Innovent Biologics Inc (6IB) — Cash Flow-to-Debt Ratio
Innovent Biologics Inc (6IB) has a Cash Flow-to-Debt Ratio of -0.04x as of June 2023, meaning its operating cash flow of €-311.45 Million could theoretically repay 0% of its total liabilities (€7.11 Billion) in one year. See free cash flow generation of Innovent Biologics Inc to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Innovent Biologics Inc Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Innovent Biologics Inc across 10 annual periods. Also explore 6IB net assets growth trend to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Innovent Biologics Inc (2016–2025)
Year-by-year debt coverage analysis for Innovent Biologics Inc. For market capitalisation and broader financial context, see 6IB stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.56x | €10.00 Billion | €17.99 Billion | ▲ +266.5% |
| 2024 | 0.15x | €1.29 Billion | €8.48 Billion | ▲ +731.2% |
| 2023 | 0.02x | €147.81 Million | €8.10 Billion | ▲ +106.5% |
| 2022 | -0.28x | €-1.92 Billion | €6.86 Billion | ▲ +18.3% |
| 2021 | -0.34x | €-2.02 Billion | €5.91 Billion | ▼ -240.0% |
| 2020 | -0.10x | €-307.69 Million | €3.06 Billion | ▲ +85.0% |
| 2019 | -0.67x | €-1.66 Billion | €2.47 Billion | ▼ -27.5% |
| 2018 | -0.53x | €-1.01 Billion | €1.92 Billion | ▼ -337.1% |
| 2017 | -0.12x | €-492.27 Million | €4.08 Billion | ▼ -25.5% |
| 2016 | -0.10x | €-362.99 Million | €3.77 Billion | — |